# Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors

> **NCT07660055** · PHASE1 · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 156 (estimated)

## Conditions studied

- Breast Cancer
- Non-small Cell Lung Cancer (NSCLC)
- Gastric/Gastroesophageal Junction (GEJ) Cancer
- Bladder Cancer

## Interventions

- **DIAGNOSTIC_TEST:** [68Ga]Ga-DWJ155
- **DRUG:** [177Lu]Lu-DWJ155

## Key facts

- **NCT ID:** NCT07660055
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-16
- **Primary completion:** 2032-05-24
- **Final completion:** 2032-05-24
- **Target enrollment:** 156 (ESTIMATED)
- **Last updated:** 2026-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07660055

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07660055, "Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07660055. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*